Health
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus® (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively, from the current list price. This decision applies to all doses of these medicines and refl
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses access barriers to our innovative medicines, especially for patients whose out-of-pocket costs are linked to list price","length":237,"tagName":"p"}]},{"val":[{"type":"text","content":"This action builds on concerted efforts from Novo Nordisk to improve patient access to Wegovy® and Ozempic® including savings offers, self-pay through NovoCare® Pharmacy, select telehealth relationships, and more","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"These changes in list price do not have an impact on direct-to-patient, self-pay prices","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy®, Ozempic®, and Rybelsus® deliver powerful efficacy in addition to offering a broad range of indications unlike other GLP-1s","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":667,"olType":false},{"type":"text","content":"PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Feb. 24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus® (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy® and Ozempic®, respectively, from the current list price. This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system.","length":776,"tagName":"p"},{"type":"text","content":""Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "Our actions today answer that call and remove cost barriers so the value of We...